ATLAS: A phase II, open-label study of rucaparib in patients (pts) with locally advanced (unresectable) or metastatic urothelial carcinoma

被引：0

作者：

Chowdhury, S. ^{[1
,2
]}

Feyerabend, S. ^{[3
]}

Loriot, Y. ^{[4
]}

Necchi, A. ^{[5
]}

Gupta, S. ^{[6
]}

Josephs, D. H. ^{[7
]}

Rodriguez-Vida, A. ^{[8
]}

Srinivas, S. ^{[9
]}

Zakharia, Y. ^{[10
,11
]}

Nepert, D. ^{[12
]}

Wride, K. ^{[13
]}

Thomas, D. ^{[14
]}

Loehr, A. ^{[15
]}

Simmons, A. D. ^{[15
]}

Grivas, P. ^{[16
]}

机构：

[1] Guys Hosp, Med Oncol, London, England

[2] Sarah Cannon Res Inst, London, England

[3] Studienpraxis Urol, Urol Oncol, Nurtingen, Germany

[4] Gustave Roussy, Dept Canc Med, Canc Campus, Villejuif, France

[5] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

[6] Univ Utah, Huntsman Canc Inst, Genitourinary Oncol Program, Salt Lake City, UT USA

[7] Guys & St Thomas Hosp, Dept Med Oncol, London, England

[8] Hosp del Mar, Genitourinary Canc Unit, Barcelona, Spain

[9] Stanford Univ, Sch Med, Urol Oncol Clin, Stanford, CA 94305 USA

[10] Univ Iowa, Div Hematol, Iowa City, IA USA

[11] Holden Comprehens Canc Ctr, Iowa City, IA USA

[12] Clovis Oncol Inc, Clin Sci, Boulder, CO USA

[13] Clovis Oncol Inc, Biostat, Boulder, CO USA

[14] Clovis Oncol Inc, Clin Operat, Boulder, CO USA

[15] Clovis Oncol Inc, Translat Med, Boulder, CO USA

[16] Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

928TiP

引用

页数：1

共 50 条

[1] ATLAS: a phase 2, open-label study of rucaparib in patients with locally advanced (unresectable) or metastatic urothelial carcinoma
Feyerabend, S.
Boegemann, M.
Goebell, P. J.
Stoeckle, M.
Nepert, D.
Wride, K.
Thomas, D.
Loehr, A.
Simmons, A.
Grivas, P.
Chowdhury, S.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 324 - 324
[2] ATLAS: A Phase II, open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma
Grivas, Petros
Teo, Min Yuen
Vogelzang, Nicholas
Alva, Ajjai
Zakharia, Yousef
Adra, Nabil
Drakaki, Alexandra
Hussain, Arif
Morales-Barrera, Rafael
Necchi, Andrea
Rodriguez-Vida, Alejo
Feyerabend, Susan
Gupta, Sumati
Josephs, Debra H.
Loriot, Yohann
Srinivas, Sandy
Wride, Kenton
Thomas, Daleen
Dusek, Rachel
Simmons, Andrew D.
Nepert, Dale
Chowdhury, Simon
CANCER RESEARCH, 2019, 79 (13)
[3] ATLAS: A phase 2, open-label study of rucaparib in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC).
Grivas, Petros
Nepert, Dale L.
Wride, Kenton
Thomas, Daleen
Loehr, Andrea
Simmons, Andrew
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[4] ATLAS: A phase II open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma (mUC).
Grivas, Petros
Vogelzang, Nicholas J.
Alva, Ajjai Shivaram
Feyerabend, Susan
Loriot, Yohann
Necchi, Andrea
Gupta, Sumati
Josephs, Debra Hannah
Rodriguez-Vida, Alejo
Srinivas, Sandy
Zakharia, Yousef
Wride, Kenton
Thomas, Daleen
Dusek, Rachel
Simmons, Andrew
Nepert, Dale L.
Chowdhury, Simon
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[5] Rucaparib for recurrent, locally advanced, or metastatic urothelial carcinoma (mUC): Results from ATLAS, a phase II open-label trial
Grivas, Petros
Loriot, Yohann
Feyerabend, Susan
Morales-Barrera, Rafael
Teo, Min Yuen
Vogelzang, Nicholas J.
Grande, Enrique
Zakharia, Yousef
Adra, Nabil
Alva, Ajjai Shivaram
Necchi, Andrea
Gupta, Sumati
Josephs, Debra Hannah
Rodriguez-Vida, Alejo
Srinivas, Sandy
Wride, Kenton
Thomas, Daleen
Dusek, Rachel
Nepert, Dale L.
Chowdhury, Simon
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[6] Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)
P. Grivas
Y. Loriot
R. Morales-Barrera
M. Y. Teo
Y. Zakharia
S. Feyerabend
N. J. Vogelzang
E. Grande
N. Adra
A. Alva
A. Necchi
A. Rodriguez-Vida
S. Gupta
D. H. Josephs
S. Srinivas
K. Wride
D. Thomas
A. Simmons
A. Loehr
R. L. Dusek
D. Nepert
S. Chowdhury
BMC Cancer, 21
[7] Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)
Grivas, P.
Loriot, Y.
Morales-Barrera, R.
Teo, M. Y.
Zakharia, Y.
Feyerabend, S.
Vogelzang, N. J.
Grande, E.
Adra, N.
Alva, A.
Necchi, A.
Rodriguez-Vida, A.
Gupta, S.
Josephs, D. H.
Srinivas, S.
Wride, K.
Thomas, D.
Simmons, A.
Loehr, A.
Dusek, R. L.
Nepert, D.
Chowdhury, S.
BMC CANCER, 2021, 21 (01)
[8] Open-label, phase II study of ladiratuzumab vedotin (LV) for unresectable locally advanced or metastatic solid tumors
Arkenau, H-T.
Guthrie, T.
Mekhail, T.
Cortinovis, D.
Antonuzzo, L.
Bruce, J. Y.
Gabrail, N.
Anderson, I.
Oh, S. C.
Oh, S. Y.
Nott, L.
Shah, M. A.
Sanborn, R. E.
Oh, D-Y.
Cho, J. Y.
Lin, C-C.
Lee, A.
Wang, Y.
Wang, Z.
Sher, A.
ANNALS OF ONCOLOGY, 2021, 32 : S671 - S672
[9] A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma
Jermann, M
Stahel, RA
Salzberg, M
Cerny, T
Joerger, M
Gillessen, S
Morant, R
Egli, F
Rhyner, K
Bauer, JA
Pless, M
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (04) : 533 - 539
[10] A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma
Monika Jermann
Rolf A Stahel
Marc Salzberg
Thomas Cerny
Markus Joerger
Silke Gillessen
Rudolf Morant
Fritz Egli
Kaspar Rhyner
Jean A Bauer
Miklos Pless
Cancer Chemotherapy and Pharmacology, 2006, 57 : 533 - 539

← 1 2 3 4 5 →